COVID-19 in the United States
The US recorded the highest COVID death toll of any country — and now navigates endemic COVID with seasonal waves, updated vaccines, and the Long COVID burden.
Pandemic Impact: By the Numbers
| Metric | Value |
| Total cases (official) | >103 million |
| Official deaths | >1.1 million |
| People with Long COVID (est.) | ~7 million (CDC 2024) |
| Vaccination rate (≥1 dose) | >77% of population |
| Public health emergency ended | May 11, 2023 |
The US Pandemic Timeline
First wave (March–June 2020): New York City became the initial epicenter; overwhelmed hospitals, PPE shortages, refrigerator trucks for bodies. The economy shut down. Emergency management was decentralized to states, creating a patchwork of policies.
Summer 2020: Second wave hit southern and western states (Florida, Texas, Arizona, California) as economies reopened prematurely.
Winter 2020–21: Deadliest phase; ~3,000–4,000 deaths per day at peak. Vaccine authorization (Pfizer-BioNTech December 11, Moderna December 18, 2020) began amid mass rollout logistics challenges.
Delta (summer–fall 2021): Delta wave caused 100,000+ daily cases and record hospitalizations in unvaccinated populations. Vaccine efficacy against severe disease remained high (>90% against Delta).
Omicron (Dec 2021–Jan 2022): Record 800,000+ daily cases at peak; overwhelmed testing capacity; less severe per infection but total hospitalizations were still enormous due to case volume.
Post-Omicron endemic phase (2022–present): Seasonal waves, declining but persistent deaths (~250–500/week), updated annual vaccines.
Current Situation (2025)
COVID-19 in the US in 2025 follows an endemic pattern with seasonal waves, predominantly in winter months (December–February) and a smaller summer wave (July–August). JN.1 descendants including KP.2, KP.1.1, and XEC are the dominant variants. Wastewater-based surveillance (CDC's NWSS) remains the most sensitive regularly updated tracking system as clinical testing has largely moved to home antigen tests with less reporting.
COVID-19 remains a significant cause of death in the US — estimated ~25,000–50,000 deaths per year in the endemic phase, comparable to or exceeding influenza. High-risk groups: adults over 65 (account for ~75% of deaths), immunocompromised, and those with multiple comorbidities.
Treatments Available in the US
- Paxlovid (nirmatrelvir/ritonavir): FDA-authorized; 5-day oral course; reduces hospitalization by ~89% in high-risk; must begin within 5 days of symptoms
- Lagevrio (molnupiravir): Less effective than Paxlovid; alternative when Paxlovid contraindicated
- Remdesivir (Veklury): IV antiviral; used in hospitalized patients
- Dexamethasone: Standard for hospitalized patients requiring supplemental oxygen
- Test-to-treat: Same-day Paxlovid prescribing at pharmacies and clinics
Long COVID in the US
Approximately 7 million Americans currently have Long COVID (defined as symptoms persisting 3+ months after acute infection, per CDC 2024 estimates). Previous estimates were higher — improvement reflects natural resolution for some patients and changing definitions. Major Long COVID symptoms: fatigue, brain fog, post-exertional malaise (PEM), POTS (postural orthostatic tachycardia syndrome), shortness of breath. The US launched the RECOVER Initiative ($1.15 billion) to study Long COVID — research is ongoing. No FDA-approved Long COVID treatment exists as of 2025.
Get COVID Outbreak Alerts
Be notified when COVID variants and outbreaks are reported in the US.
Frequently Asked Questions
COVID-19 remains a significant health risk, particularly for adults over 65, immunocompromised individuals, and those with multiple chronic conditions. Annual deaths are estimated at 25,000–50,000. For healthy younger adults, individual risk is low but Long COVID risk after each infection provides reason to continue preventing infection where possible.
CDC recommends the updated 2024–25 COVID vaccine for everyone 6 months and older. Adults 65+ and immunocompromised individuals are recommended to receive an additional dose in the same season. The updated vaccine targets JN.1 descendants which are currently dominant in the US.
Paxlovid is available by prescription. Under the US test-to-treat program, many pharmacies can prescribe and dispense Paxlovid in the same visit. Telehealth services also provide same-day prescriptions. It must be started within 5 days of symptom onset. Check for drug interactions — Paxlovid has significant interactions with many common medications (statins, blood thinners, etc.).
Sources: CDC COVID Data Tracker; CDC NWSS Wastewater Surveillance; FDA Paxlovid authorization; HHS RECOVER Initiative; Johns Hopkins Coronavirus Resource Center (archived).
Related: COVID-19 overview · How COVID variants work